检索范围:
排序: 展示方式:
Developing effective tumor vaccines: basis, challenges and perspectives
XU Qingwen, CHEN Weifeng
《医学前沿(英文)》 2007年 第1卷 第1期 页码 11-19 doi: 10.1007/s11684-007-0003-9
关键词: development conventional identification elucidation Successful immunotherapy
Prospects of immunotherapy for cancer
Zhinan Chen
《医学前沿(英文)》 2019年 第13卷 第1期 页码 1-2 doi: 10.1007/s11684-019-0691-y
Immunometabolism: a new dimension in immunotherapy resistance
《医学前沿(英文)》 2023年 第17卷 第4期 页码 585-616 doi: 10.1007/s11684-023-1012-z
关键词: immune cell immunometabolism metabolic reprogramming immunotherapy resistance tumor microenvironment immune checkpoint inhibitor
Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine
Hongmei Xu, Xuetao Cao
《医学前沿(英文)》 2011年 第5卷 第4期 页码 323-332 doi: 10.1007/s11684-011-0172-4
Challenges of NK cell-based immunotherapy in the new era
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 440-450 doi: tzg@ustc.edu.cn
Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells (PBMCs), stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.
关键词: natural killer cells immunotherapy adoptive transfer genetic modification immune checkpoint inhibitor
《工程管理前沿(英文)》 2022年 第9卷 第1期 页码 159-162 doi: 10.1007/s42524-021-0183-z
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
《医学前沿(英文)》 2021年 第15卷 第6期 页码 783-804 doi: 10.1007/s11684-021-0904-z
Functional tolerance theory in incremental growth design
YANG Bo, ZE Xiangbo, YANG Tao
《机械工程前沿(英文)》 2007年 第2卷 第3期 页码 336-343 doi: 10.1007/s11465-007-0059-x
关键词: successful transformation mathematical automation technology tolerance allocation minimum
Qinghua HE, Junyan XU, Ting WANG, Albert P. C. CHAN
《工程管理前沿(英文)》 2021年 第8卷 第1期 页码 5-16 doi: 10.1007/s42524-019-0058-8
关键词: megaproject management driving factors project success case study China
调节性T细胞及其在抗肿瘤免疫疗法中的临床应用 Review
解丰, 梁瑞, 李丹, 李斌
《工程(英文)》 2019年 第5卷 第1期 页码 132-139 doi: 10.1016/j.eng.2018.12.002
癌症是可能危及生命的疾病,特点在于肿瘤细胞在宿主身上无限增殖。最近,因其具有预防肿瘤进展和转移的巨大潜力,免疫疗法受到越来越多研究者的关注。调节性T 细胞(Treg)是对维持宿主免疫稳态起重要作用的抑制性CD4+ T 细胞的一个亚群。调节性T 细胞缺陷可引起严重的自身免疫、过敏和自身炎症等疾病。调节性T 细胞通常富集在肿瘤微环境中,而大量免疫抑制调节性T细胞往往表明预后较差。因此,人们对调节性T 细胞的功能及其在抗肿瘤免疫疗法中的临床应用再次产生了兴趣。越来越多的策略关注调节性T 细胞的消耗,这在抗肿瘤免疫方面似乎有效。预计调节性T 细胞靶向策略与其他疗法(如嵌合抗原受体T 细胞疗法或免疫检查点阻断)联用将为提高抗肿瘤疗效带来重大机遇。
Chuangnian Zhang, Ying Dong, Jing Gao, Xiaoli Wang, Yanjun Jiang
《化学科学与工程前沿(英文)》 2021年 第15卷 第5期 页码 1296-1311 doi: 10.1007/s11705-020-2034-6
关键词: silica nanoflower antigen delivery cancer immunotherapy nanovaccine
《医学前沿(英文)》 2022年 第16卷 第1期 页码 139-149 doi: 10.1007/s11684-021-0835-8
关键词: B-cell acute lymphoblastic leukemia bispecific antibody trispecific antibody CD19 CD20
Activation of phagocytosis by immune checkpoint blockade
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 473-480 doi: 10.1007/s11684-018-0657-5
Inhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immune evasion. One mechanism inhibiting the innate response is the presence of the macrophage inhibitory molecule, signal regulatory protein-α (SIRPα), on tumor-associated macrophages (TAMs) and its cognate ligand cluster of differentiation 47 (CD47) on tumor cells in the tumor microenvironment. On the basis of a recently discovered programmed death protein 1 (PD-1) in TAMs, we discuss the potential inhibitory receptors that possess new functions beyond T cell exhaustion in this review. As more and more immune receptors are found to be expressed on TAMs, the corresponding therapies may also stimulate macrophages for phagocytosis and thereby provide extra anti-tumor benefits in cancer therapy. Therefore, identification of biomarkers and combinatorial therapeutic strategies, have the potential to improve the efficacy and safety profiles of current immunotherapies.
关键词: CD47 PD-1 PD-L1 immunotherapy TAM phagocytosis macrophage
标题 作者 时间 类型 操作
Developing effective tumor vaccines: basis, challenges and perspectives
XU Qingwen, CHEN Weifeng
期刊论文
Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine
Hongmei Xu, Xuetao Cao
期刊论文
Engineers as business leaders: A need to investigate formative collegiate experiences of highly successful
期刊论文
Identifying the driving factors of successful megaproject construction management: Findings from three
Qinghua HE, Junyan XU, Ting WANG, Albert P. C. CHAN
期刊论文
and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy
期刊论文